Charles River Laboratories International, Inc. (CRL)
Automate Your Wheel Strategy on CRL
With Tiblio's Option Bot, you can configure your own wheel strategy including CRL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRL
- Rev/Share 81.5869
- Book/Share 65.247
- PB 2.543
- Debt/Equity 0.9687
- CurrentRatio 1.2916
- ROIC 0.0706
- MktCap 8047713818.0
- FreeCF/Share 10.5351
- PFCF 15.5213
- PE -55.7566
- Debt/Assets 0.4296
- DivYield 0
- ROE -0.044
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CRL | BofA Securities | Neutral | Buy | -- | $225 | Dec. 15, 2025 |
| Upgrade | CRL | Argus | Hold | Buy | -- | -- | Nov. 17, 2025 |
| Upgrade | CRL | Robert W. Baird | Neutral | Outperform | -- | $199 | Nov. 6, 2025 |
| Upgrade | CRL | William Blair | Market Perform | Outperform | -- | -- | Oct. 6, 2025 |
| Upgrade | CRL | Barclays | Equal Weight | Overweight | -- | $195 | Oct. 2, 2025 |
| Upgrade | CRL | Jefferies | Hold | Buy | -- | $195 | Sept. 9, 2025 |
| Upgrade | CRL | Citigroup | Neutral | Buy | -- | $200 | July 9, 2025 |
| Upgrade | CRL | Redburn Atlantic | Neutral | Buy | -- | $182 | May 23, 2025 |
| Upgrade | CRL | TD Cowen | Hold | Buy | -- | $179 | May 14, 2025 |
| Upgrade | CRL | Evercore ISI | In-line | Outperform | -- | $170 | May 8, 2025 |
News
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
Published: February 18, 2026 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
Read More
Charles River Laboratories Q4 Review: Approaching A Bottom
Published: February 18, 2026 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories Q4 Review: Approaching A Bottom
Read More
Here's What Key Metrics Tell Us About Charles River (CRL) Q4 Earnings
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Neutral
Charles River tops Q4 earnings and revenue estimates as margins expand, but shares dip, and organic growth declines across all segments.
Read More
Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
Charles River Laboratories (CRL) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $2.66 per share a year ago.
Read More
What Analyst Projections for Key Metrics Reveal About Charles River (CRL) Q4 Earnings
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Charles River (CRL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Read More
Here's How Charles River Stock Is Placed Ahead of Q4 Earnings
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Neutral
CRL heads into Q4 earnings with collaborations and strength in RMS and Manufacturing, even as DSA headwinds weigh on revenue expectations.
Read More
Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Published: February 12, 2026 by: GlobeNewsWire
Sentiment: Neutral
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights
Read More
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Negative
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Charles River Laboratories Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
Published: January 20, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK and NEW ORLEANS, Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Read More
Here's Why Charles River Laboratories (CRL) is a Great Momentum Stock to Buy
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
What Makes Charles River (CRL) a New Buy Stock
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Charles River (CRL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Should You Continue to Hold CRL Stock in Your Portfolio for Now?
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River gains from strong RMS demand, strategic partnerships and solid finances but faces macro and competitive pressures in 2025.
Read More
Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Published: December 01, 2025 by: PRNewsWire
Sentiment: Neutral
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders.
Read More
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. ( CRL ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Birgit Girshick - Corporate Executive VP & COO Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division All right. Good morning, everybody.
Read More
Charles River (CRL) International Revenue Performance Explored
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Read More
Charles River Laboratories International, Inc. (CRL) Q3 2025 Earnings Call Transcript
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. ( CRL ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - Chairman, President & CEO Michael Knell - Interim CFO, Corporate Senior VP & Chief Accounting Officer Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division David Windley - Jefferies LLC, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Justin Bowers - Deutsche Bank AG, Research Division Casey Woodring - JPMorgan Chase & Co, …
Read More
Charles River Beat Expectations But Why Is The Stock Falling?
Published: November 05, 2025 by: Benzinga
Sentiment: Negative
Charles River Laboratories International Inc. (NYSE:CRL) stock is trading lower on Wednesday after the company released third-quarter 2025 earnings. It also provided an update on the company's strategic review.
Read More
Charles River: Mixed Q3 As Strategic Review Disappoints
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Negative
Charles River Laboratories remains a "Hold" as strategic review yields minimal change and a sale is unlikely. CRL faces slow organic growth, shrinking backlog, and ongoing pressure in its core DSA segment, with limited near-term demand recovery. Cost-cutting, selective divestitures, and a new $1 billion buyback authorization offer some support, but growth headwinds persist.
Read More
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
CRL's Q3 Earnings Top Estimates, Revenues Decline Y/Y, Stock Falls
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Charles River beats Q3 profit and revenue forecasts but posts year-over-year declines and narrows its 2025 outlook.
Read More
Charles River Laboratories (CRL) Q3 Earnings and Revenues Surpass Estimates
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River Laboratories (CRL) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.32 per share. This compares to earnings of $2.59 per share a year ago.
Read More
Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Published: October 24, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders. If you currently own Charles River stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click he.
Read More
Here's How Charles River Stock Is Placed Ahead of Q3 Earnings
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
CRL heads into Q3 earnings with steady RMS growth but faces DSA headwinds from tight biotech budgets.
Read More
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
3 Medical Service Industry Stocks Poised to Counter Workforce Issues
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Here are three resilient medical services stocks, Labcorp, Charles River Laboratories and Teladoc, that are poised to outperform amid staffing shortages and digital healthcare growth.
Read More
About Charles River Laboratories International, Inc. (CRL)
- IPO Date 2000-06-23
- Website https://www.criver.com
- Industry Medical - Diagnostics & Research
- CEO James C. Foster
- Employees 18700